The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InVertex Pharmaceuticals reported a significant rebound in its CRISPR gene-edited therapy sales during the final quarter of 2025. The company's breakthrough treatment, Casgevy, generated $54 million in revenue, representing a threefold increase compared to the previous quarter. This strong performance contributed to a total annual revenue of $12 billion for the year 2025, exceeding market expectations. Investor confidence surged following the results, driving a jump in the company's stock price as commercial adoption of the therapy accelerated. Analysts attribute the growth to increased patient uptake and an optimistic outlook for future FDA approvals targeting younger demographics. The success of Casgevy marks a pivotal moment for the commercialization of gene-editing technologies in the biotech sector.